Prognostic significance of WBC, age, and cytogenetics in patients with core binding factor acute myeloid leukemia (CBF-AML): A comparative study from the French AML Intergroup.

被引：0
|
作者：
Delaunay, J
Leblanc, T
Blaise, D
Fenaux, P
Huguet-Rigal, F
Witz, F
Pigneux, A
Thomas, X
Auvrignon, A
Colombat, P
Lioure, B
Van den Akker, J
Mugneret, F
Bastard, C
Dastugue, N
Castaigne, S
Reiffers, J
Leverger, G
Harousseau, JL
Dombret, H
机构：
[1] Hop St Louis, Paris, France
[2] IPC, Marseille, France
[3] Hop Claude Huriez, Lille, France
[4] Hop Purpan, Toulouse, France
[5] Hop Brabois, Nancy, France
[6] Hop Haut Leveque, Bordeaux, France
[7] Hop Edouard Herriot, Lyon, France
[8] Hop Trousseau, F-75571 Paris, France
[9] Hop Bretonneau, Tours, France
[10] Hop Hautepierre, Strasbourg, France
[11] Hop St Antoine, F-75571 Paris, France
[12] Hop Bocage, Dijon, France
[13] Ctr Henri Becquerel, F-76038 Rouen, France
[14] Hop Andre Mignot, Versailles, France
[15] Hop Hotel Dieu, Nantes, France
来源：
BLOOD | 2002年 / 100卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2960
引用
收藏
页码：748A / 748A
页数：1
相关论文
共 50 条
  • [41] Overweight is An Independent Adverse Prognostic Factor in Acute Myeloid Leukemia (AML) in Younger Patients
    Capovilla, S.
    Herold, T.
    Sauerland, C.
    Berdel, W.
    Woermann, B.
    Buechner, T.
    Hiddemann, W.
    Fiegl, M.
    ANNALS OF HEMATOLOGY, 2015, 94 (SUPPL 1) : 76 - 77
  • [42] Prognosis of inv(16)/t(16;16) acute myeloid leukemia (AML):: a survey of 110 cases from the French AML Intergroup
    Delaunay, J
    Vey, N
    Leblanc, T
    Fenaux, P
    Rigal-Huguet, F
    Witz, F
    Lamy, T
    Auvrignon, A
    Blaise, D
    Pigneux, A
    Mugneret, F
    Bastard, C
    Dastugue, N
    Van den Akker, J
    Fière, D
    Reiffers, J
    Castaigne, S
    Leverger, G
    Harousseau, JL
    Dombret, H
    BLOOD, 2003, 102 (02) : 462 - 469
  • [43] Prognostic Significance of Histone (H4) Acetylation In Newly Diagnosed Acute Myeloid Leukemia (AML) Patients with Intermediate Risk Cytogenetics
    Shadman, Mazyar
    Gibson, Sarah
    Cotta, Claudiu
    Saunthararajah, Yogen
    Hsi, Eric
    Copelan, Edward
    Kalaycio, Matt
    Sekeres, Mikkael A.
    Sobecks, Ronald
    Effinger, Meagan
    Advani, Anjali S.
    BLOOD, 2010, 116 (21) : 1128 - 1128
  • [44] Residual Allelic Burden Measured By Next-Generation Sequencing (NGS) at Remission Provides Limited Prognostic Value to Predict Relapse and Long-Term Outcome in Core Binding Factor Acute Myeloid Leukemia (CBF-AML)
    Kim, Taehyung
    Moon, Joon Ho
    Ahn, Jae-Sook
    Tyndel, Marc S.
    Lee, Seung-Shin
    Ahn, Seo-Yeon
    Jung, Sung-Hoon
    Yang, Deok-Hwan
    Lee, Je-Jung
    Choi, Seunghyun
    Lee, Ja-yeon
    Lee, Yoojin
    Sohn, Sang Kyun
    Kim, Hyeoung-Joon
    Zhang, Zhaolei
    Kim, Dennis Dong Hwan
    BLOOD, 2018, 132
  • [45] Core Binding Factor Acute Myeloid Leukemia in Pediatric Patients of the AIEOP AML 2002/01 Trial: Screening and Prognostic Impact of CKIT Mutations
    Manara, Elena
    Bisio, Valeria
    Beqiri, Valzerda
    Rondelli, Roberto
    Menna, Giuseppe
    Micalizzi, Concetta
    Santoro, Nicola
    Locatelli, Franco
    Basso, Giuseppe
    Pigazzi, Martina
    JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2014, 36 (04) : 323 - 323
  • [46] Minimal Residual Disease Monitored With Fluorescence In Situ Hybridization (FISH) In CD34+CD38- Population Predicts Clinical Outcome In Core Binding Factor Acute Myeloid Leukemia (CBF-AML)
    Hu, Xiaoxia
    Wang, Libing
    Gao, Lei
    Xu, Sheng
    Gong, Shenglan
    Liu, Min
    Qiu, Huiying
    Xu, Xiaoqian
    Ni, Xiong
    Chen, Li
    Lu, Shuqing
    Chen, Jie
    Song, Xianmin
    Zhang, Weiping
    Yang, Jianmin
    Wang, Jianmin
    BLOOD, 2013, 122 (21)
  • [47] Factors Influencing Complete Remission (CR) Rate in Patients ≥ 60 Years with Acute Myeloid Leukemia (AML): Report From the German AML Intergroup Study
    Niederwieser, Dietger
    Hoffmann, Verena S.
    Krahl, Rainer
    Berdel, Wolfgang E.
    Sauerland, Maria Cristina
    Hiddemann, Wolfgang
    Hegenbart, Ute
    Woermann, Bernhard Josef
    Krug, U.
    Poenisch, Wolfram
    Vucinic, Vladan
    Hebenstreit, Karin
    Cross, Michael
    Niederwieser, Christian
    Pfirrmann, Markus
    Schulze, A.
    Kraemer, Alwin
    Maschmeyer, Georg
    Freund, Mathias
    Scholl, S.
    Heinicke, Thomas
    Haehling, D.
    Wolf, Hans-Heinrich
    Buechner, Thomas
    BLOOD, 2012, 120 (21)
  • [48] Albumin as a prognostic factor for overall survival in newly diagnosed patients with acute myeloid leukemia (AML).
    Khan, Awais M.
    Lancet, Jeffrey E.
    Kharfan-Dabaja, Mohamed A.
    Al Ali, Najla
    List, Alan F.
    Komrokji, Rami S.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [49] Overexpression of the ERG gene is an adverse prognostic factor in acute myeloid leukemia (AML) with normal cytogenetics (NC):: A cancer and leukemia group B study (CALGB).
    Marcucci, G
    Baldus, CD
    Ruppert, AS
    Radmacher, MD
    Mrózek, K
    Whitman, SP
    Kolitz, JE
    Edwards, CG
    Vardiman, J
    Powell, BL
    Baer, MR
    Moore, JO
    Perrotti, D
    Caligiuri, MA
    Carroll, AJ
    Larson, RA
    de la Chapelle, A
    Bloomfield, CD
    BLOOD, 2005, 106 (11) : 101A - 101A
  • [50] Dynamics of Molecular Response in Patients (pts) with Acute Myeloid Leukemia (AML) Withy Core Binding Factor (CBF) Abnormalities Treated with High-Dose Cytarabine Regimen
    Jabbour, Elias J.
    Kantarjian, Hagop M.
    Cameron, Yin
    Ravandi, Farhad
    Cortes, Jorge E.
    Garcia-Manero, Guillermo
    Ghanem, Hady
    Kadia, Tapan M.
    Faderl, Stefan
    O'Brien, Susan
    Mathisen, Michael S.
    Brandt, Mark
    Pemmaraju, Naveen
    Thomas, Deborah A.
    Bass, Joyce
    Borthakur, Gautam
    BLOOD, 2012, 120 (21)
12345